Alto Neuroscience, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Amit Etkin
- Full Time Employees
- 68
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 650 Castro Street Mountain View CA United States of America 94041
- IPO Date
- Feb 2, 2024
- CIK
- 0001999480
- Website
- altoneuroscience.com
- Similar Companies
- Business
- Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in the development of precision medicines for neuropsychiatric disorders. Founded in 2019 and headquartered in California, the company leverages its proprietary Precision Psychiatry Platform™ to measure brain biomarkers through analysis of electroencephalography (EEG) activity, neurocognitive assessments, wearable data, genetics, and behavioral patterns. Its core products include clinical-stage drug candidates such as ALTO-100, ALTO-101, ALTO-202, ALTO-203, and ALTO-300, which target major depressive disorder, bipolar depression, schizophrenia, treatment-resistant depression, and post-traumatic stress disorder. Alto's platform integrates artificial intelligence-derived brain biomarkers to personalize treatment approaches for individual patients, aiming to improve clinical response and outcomes. In the past two years, Alto Neuroscience has made significant advances including a successful FDA meeting for ALTO-207, a treatment for treatment-resistant depression, which has enabled acceleration of its development. The company secured $50 million in private placement financing in 2025 to support the initiation of a Phase 2b clinical trial by mid-2026 and plans to
Company News
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
AWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANRO
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Analysts
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience (NYSE:ANRO) Shares Gap Down Following Analyst Downgrade
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights